StockData
Janux Therapeutics, Inc. logo

Janux Therapeutics, Inc. (JANX) stock

JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3037% below fair value
$10.71−0.21 (-1.92%)

Close on Nov 17, 2026Market cap $654.78MP/E –Yield –

Janux Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Janux Therapeutics's price to book ratio was 0.8× on Nov 11, 2026, against 2.1× a year earlier. Over the last 5 years it ranged from 0.8× to 7.7×, with a median of 1.6×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.8×−0.0
2025Dec 31, 20250.8×−3.4
2024Dec 31, 20244.3×+2.9
2023Dec 29, 20231.4×−0.2
2022Dec 30, 20221.7×−0.5
2021Dec 31, 20212.2×–

More Janux Therapeutics figures

See a number that looks wrong?